KR0159114B1 - 인지질이 피복된 미세결정성 수불용성 약제의 주사형 제제 - Google Patents

인지질이 피복된 미세결정성 수불용성 약제의 주사형 제제 Download PDF

Info

Publication number
KR0159114B1
KR0159114B1 KR1019920702656A KR920702656A KR0159114B1 KR 0159114 B1 KR0159114 B1 KR 0159114B1 KR 1019920702656 A KR1019920702656 A KR 1019920702656A KR 920702656 A KR920702656 A KR 920702656A KR 0159114 B1 KR0159114 B1 KR 0159114B1
Authority
KR
South Korea
Prior art keywords
water
drug
microcrystals
lecithin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019920702656A
Other languages
English (en)
Korean (ko)
Inventor
에이취. 헤이네스 던칸
Original Assignee
에이취. 헤이네스 던칸
파르마-로직 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이취. 헤이네스 던칸, 파르마-로직 인코포레이티드 filed Critical 에이취. 헤이네스 던칸
Application granted granted Critical
Publication of KR0159114B1 publication Critical patent/KR0159114B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019920702656A 1990-04-26 1991-04-23 인지질이 피복된 미세결정성 수불용성 약제의 주사형 제제 Expired - Lifetime KR0159114B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/514,012 US5091188A (en) 1990-04-26 1990-04-26 Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US90-514,012 1990-04-26

Publications (1)

Publication Number Publication Date
KR0159114B1 true KR0159114B1 (ko) 1998-12-01

Family

ID=24045456

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702656A Expired - Lifetime KR0159114B1 (ko) 1990-04-26 1991-04-23 인지질이 피복된 미세결정성 수불용성 약제의 주사형 제제

Country Status (16)

Country Link
US (2) US5091188A (enExample)
EP (1) EP0533690B1 (enExample)
JP (1) JP3261129B2 (enExample)
KR (1) KR0159114B1 (enExample)
AT (1) ATE181234T1 (enExample)
AU (1) AU7852891A (enExample)
CA (1) CA2078990C (enExample)
DE (1) DE69131349T2 (enExample)
DK (1) DK0533690T3 (enExample)
ES (1) ES2134776T3 (enExample)
GR (1) GR3030825T3 (enExample)
MX (1) MX25532A (enExample)
RU (1) RU2100030C1 (enExample)
TW (1) TW203559B (enExample)
WO (1) WO1991016068A1 (enExample)
ZA (1) ZA913122B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100836035B1 (ko) * 2002-02-19 2008-06-09 (주)아모레퍼시픽 포화 및 불포화 레시틴 함유 나노에멀젼 및 이를 함유하는화장료 조성물
KR101054234B1 (ko) * 2002-06-28 2011-08-08 에디컨인코포레이티드 서방출을 위한 중합체 피복된 미세입자

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1993015731A1 (en) * 1992-02-14 1993-08-19 Robert Lamb Phosphate derivatives of vitamin e to protect cells from effects of aging and injury
DE4221268C2 (de) * 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
DE19609538A1 (de) * 1996-03-11 1997-09-18 Basf Ag Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung
DE4322158C2 (de) * 1993-07-03 1997-04-10 Rhone Poulenc Rorer Gmbh Phospholipidische Zusammensetzung sowie Verwendung einer derartigen Zusammensetzung
US5393461A (en) * 1993-10-04 1995-02-28 Rtd Corporation Preparation of stable aqueous emulsions of water-insoluble particles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
DE19511276C2 (de) * 1995-03-27 1999-02-18 Immuno Ag Adjuvans auf der Basis kolloidaler Eisenverbindungen
US5788959A (en) 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
DE69637441T2 (de) * 1995-10-17 2009-03-05 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
ATE203157T1 (de) 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
FR2757768B1 (fr) * 1996-12-27 1999-04-02 Biovector Therapeutics Sa Vecteur particulaire homeocharge et composition pharmaceutique ou cosmetique le contenant
JP4153563B2 (ja) * 1997-02-27 2008-09-24 ノバルティス アーゲー 医薬組成物
AU7133898A (en) * 1997-04-18 1998-11-13 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
KR100904931B1 (ko) * 1997-06-27 2009-06-29 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
NZ504894A (en) * 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2320807C (en) * 1998-02-11 2011-01-18 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US7343710B2 (en) * 1998-07-03 2008-03-18 I.D.A Limited Method and apparatus for controlling pests
GB9814507D0 (en) * 1998-07-03 1998-09-02 Univ Southampton A method and apparatus for controlling pests
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
ES2259846T3 (es) * 1998-10-19 2006-10-16 Powderject Vaccines, Inc. Promotores minimo y uso de los mismos.
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
BR9915738A (pt) * 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
DE19901687B4 (de) * 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
KR100359252B1 (ko) * 1999-12-21 2002-11-04 주식회사 엘지생명과학 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU3606100A (en) * 1999-02-26 2000-09-14 Idexx Laboratories, Inc. Methods for administering pharmacologically active compounds to vertebrates
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6551842B1 (en) 1999-03-26 2003-04-22 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ATE519372T1 (de) * 1999-07-16 2011-08-15 Unilever Nv Flüssige fettdispersionen
CN100406004C (zh) 1999-08-24 2008-07-30 特瓦制药工业有限公司 疫苗组合物及其制药用途
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
IL148685A0 (en) * 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
US7045049B1 (en) 1999-10-01 2006-05-16 Nanoplex Technologies, Inc. Method of manufacture of colloidal rod particles as nanobar codes
US7225082B1 (en) * 1999-10-01 2007-05-29 Oxonica, Inc. Colloidal rod particles as nanobar codes
US20050032226A1 (en) * 1999-10-01 2005-02-10 Natan Michael J. Encoded nanoparticles in paper manufacture
US20040209376A1 (en) * 1999-10-01 2004-10-21 Surromed, Inc. Assemblies of differentiable segmented particles
US6919009B2 (en) * 1999-10-01 2005-07-19 Nanoplex Technologies, Inc. Method of manufacture of colloidal rod particles as nanobarcodes
US20040178076A1 (en) * 1999-10-01 2004-09-16 Stonas Walter J. Method of manufacture of colloidal rod particles as nanobarcodes
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
WO2001080828A2 (en) 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
AU5967101A (en) 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
WO2001097779A2 (en) 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US6579519B2 (en) * 2000-09-18 2003-06-17 Registrar, University Of Delhi Sustained release and long residing ophthalmic formulation and the process of preparing the same
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
NZ525231A (en) * 2000-09-20 2004-08-27 Skyepharma Canada Inc Phospholipid stabilised feno-fibrate microparticles for pharmaceutical use
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
SI1343529T1 (sl) * 2000-12-19 2009-04-30 Univ Texas NSAID formulacije, ki vsebujejo lecitinska olja, za zaščito gastrointestinalnega trakta in zagotovitev povečanja terapevtske aktivnosti
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6497896B2 (en) 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
AU2001259099B2 (en) * 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20020176841A1 (en) * 2001-03-19 2002-11-28 Praecis Pharmaceuticals Inc. Pharmaceutical formulations for sustained release
PT1389089E (pt) * 2001-03-27 2009-11-30 Phares Pharm Res Nv Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
US20020146745A1 (en) * 2001-04-03 2002-10-10 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
EP1392245A2 (en) * 2001-04-05 2004-03-03 Universite Laval Process for making protein delivery matrix and uses thereof
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
PL211116B1 (pl) * 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US7838034B2 (en) * 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
ES2363221T3 (es) 2002-10-16 2011-07-27 Purdue Pharma L.P. Anticuerpos que se unen a ca 125/0722p asociado a células y métodos de uso de los mismos.
BR0215979A (pt) * 2002-12-13 2005-11-01 Jagotec Ag Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
RU2331424C2 (ru) * 2002-12-13 2008-08-20 Джеготек Аг Топический состав, содержащий наночастицы спиронолактона
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1603513B1 (en) 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2004113869A2 (en) * 2003-06-17 2004-12-29 Surromed, Inc. Labeling and authentication of metal objects
DE10327839A1 (de) * 2003-06-20 2005-01-05 Arvinmeritor Gmbh Fahrzeugdachmodul
BRPI0414970A2 (pt) * 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US20080051373A1 (en) * 2003-07-31 2008-02-28 The Board Of Regents Of The University Of Texas System Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
JP2005097295A (ja) * 2003-09-01 2005-04-14 Wakunaga Pharmaceut Co Ltd ビタミン安定液剤
BRPI0414321B8 (pt) 2003-09-22 2021-06-22 Baxter Healthcare Sa esterilização à alta pressão para esterilização final de preparações farmacêuticas e produtos médicos
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CN1917859A (zh) * 2003-12-24 2007-02-21 日本株式会社Ltt生物医药 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂
US20050202094A1 (en) * 2004-01-29 2005-09-15 Werling Jane O. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
JP2008501034A (ja) * 2004-05-28 2008-01-17 シェーリング　コーポレイション ポサコナゾールを含む注射用薬学的懸濁液
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
BRPI0510271A (pt) * 2004-06-15 2007-10-30 Baxter Int aplicações ex-vivo agentes terapêuticos microparticulados
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
BRPI0612071A2 (pt) * 2005-06-14 2010-10-19 Baxter Int formulações farmacêuticas para minimizar interações entre fármacos
CN101309669A (zh) * 2005-11-15 2008-11-19 巴克斯特国际公司 脂氧合酶抑制剂的组合物
WO2007115134A2 (en) 2006-03-29 2007-10-11 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2008054508A2 (en) * 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
WO2008013822A2 (en) * 2006-07-26 2008-01-31 The Board Of Regent Of The University Of Texas System Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
US20110021592A1 (en) * 2006-09-14 2011-01-27 Shlomo Magdassi Organic nanoparticles obtained from microemulsions by solvent evaporation
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2152274A4 (en) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc NASAL ADMINISTRATION OF BENZODIAZEPINES
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
EP2244783B1 (en) * 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009111638A1 (en) 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
ES2586032T3 (es) * 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
KR20110099138A (ko) * 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
KR20110098849A (ko) * 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP3195896A1 (en) 2009-05-05 2017-07-26 Board of Regents, The University of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
PL2552930T3 (pl) 2010-03-31 2016-02-29 Gilead Pharmasset Llc Krystaliczny 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1-(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian (S)-izopropylu
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
EP2646107A2 (en) 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL3415139T3 (pl) 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
MX356017B (es) 2011-09-29 2018-05-08 Plx Opco Inc Portadores dependientes de ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricacion y uso de las mismas.
WO2013049941A1 (en) 2011-10-06 2013-04-11 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
CN113712911A (zh) 2013-03-15 2021-11-30 维普詹尼克斯公司 新型镇痛组合物
RU2541156C1 (ru) * 2013-07-09 2015-02-10 Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" Трансдермальное антигельминтное средство на основе кремнийорганических ниосом с альбендазолом
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017097855A1 (en) * 2015-12-08 2017-06-15 Verano Ilac Sanayi Ticaret Anonim Sirketi An injectable composition of ricobendazole
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
CN115666523A (zh) 2020-03-26 2023-01-31 Plx 奥普科有限公司 能够进行pH依赖性重构的药物载体及其制备和使用方法
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN116687847B (zh) * 2023-06-26 2024-03-29 石家庄四药有限公司 一种药物微晶注射液及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4298594A (en) * 1978-04-14 1981-11-03 Arthur D. Little, Inc. Xenobiotic delivery vehicles, method of forming them and method of using them
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4421747A (en) * 1978-12-27 1983-12-20 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4378354A (en) * 1978-12-27 1983-03-29 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
JPS562353A (en) * 1979-06-20 1981-01-12 Ricoh Co Ltd Novel disazo compound and its preparation
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
AR220263A1 (es) * 1980-02-19 1980-10-15 Bago Lab Sa Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
JPH0617309B2 (ja) * 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
EP0256119A4 (en) * 1986-02-10 1988-08-23 Liposome Technology Inc MAINTAINED LIPOSOME DELIVERY SYSTEM.
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
JPS62278241A (ja) * 1986-05-26 1987-12-03 Shoei Kagaku Kogyo Kk ボンデイングワイヤ
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
DK175531B1 (da) * 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100836035B1 (ko) * 2002-02-19 2008-06-09 (주)아모레퍼시픽 포화 및 불포화 레시틴 함유 나노에멀젼 및 이를 함유하는화장료 조성물
KR101054234B1 (ko) * 2002-06-28 2011-08-08 에디컨인코포레이티드 서방출을 위한 중합체 피복된 미세입자

Also Published As

Publication number Publication date
JPH05507685A (ja) 1993-11-04
DK0533690T3 (da) 1999-11-22
AU7852891A (en) 1991-11-11
DE69131349T2 (de) 1999-11-18
EP0533690A1 (en) 1993-03-31
RU2100030C1 (ru) 1997-12-27
CA2078990A1 (en) 1991-10-27
EP0533690B1 (en) 1999-06-16
US5091188A (en) 1992-02-25
MX25532A (es) 1993-10-01
DE69131349D1 (de) 1999-07-22
WO1991016068A1 (en) 1991-10-31
JP3261129B2 (ja) 2002-02-25
ZA913122B (en) 1992-04-29
ES2134776T3 (es) 1999-10-16
EP0533690A4 (en) 1993-04-14
GR3030825T3 (en) 1999-11-30
ATE181234T1 (de) 1999-07-15
USRE35338E (en) 1996-09-24
CA2078990C (en) 2002-06-04
TW203559B (enExample) 1993-04-11

Similar Documents

Publication Publication Date Title
KR0159114B1 (ko) 인지질이 피복된 미세결정성 수불용성 약제의 주사형 제제
US5091187A (en) Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5188837A (en) Lipsopheres for controlled delivery of substances
JP2518605B2 (ja) 水不溶性薬剤を含む微小滴
CA2162993C (en) Solid fat nanoemulsions as drug delivery vehicles
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
JP3026271B2 (ja) 活性薬剤の制御放出に用いる多小胞リポソームの調製
Da Silva et al. Nanotechnology-based drug delivery systems for treatment of tuberculosis—a review
Tice et al. Parenteral drug delivery: injectables
US20030235619A1 (en) Polymer-lipid delivery vehicles
US20060177495A1 (en) Polymer-lipid delivery vehicles
JP5627039B2 (ja) 薬物のナノ分散体およびその調製のための方法
CA2069760C (en) Lipid formulation system
IL272187B (en) Liposome preparations containing weak acid drugs and uses thereof
PT981328E (pt) Composição formadora de uma emulsão para um composto taxóide.
US20030211140A1 (en) Oil-core compositions for the sustained release of hydrophobic drugs
CN101653414A (zh) 多西他赛长循环固体脂质纳米粒及其制备方法
KR20000049266A (ko) 장벽을 통한 활성성분 운반용 제제
Lakshmi et al. Ufasomes: A potential vesicular carrier system
US20080193509A1 (en) Liposome Preparation Containing Slightly Water-Soluble Camptothecin
CN100502834C (zh) 两性霉素b结构化乳剂
JP4719355B2 (ja) パルトリシン誘導体の注射可能な薬学的処方物
Yadav et al. Formulation and evaluation of ethosome of mefenamic acid using hot method
BR112021003256A2 (pt) composição farmacêutica, método para tratar uma doença respiratória e método para reduzir o efeito colateral de uma droga de ácido fraco

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19921026

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19940506

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19960409

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19921026

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980622

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980810

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980810

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010811

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020809

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030808

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041004

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050805

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060808

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070723

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080708

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20090717

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20100719

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20100719

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20120110

Termination category: Expiration of duration